CliffBio
small molecule

REMERON

MIRTAZAPINE

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameREMERON
Active ingredientMIRTAZAPINE
Strength15MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 1996
Marketing statusRX

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

REMERON patent cliff — loss of exclusivity — | CliffBio